GLP-1 Headline Quiz: Fact, Spin or Missing Context?

C) Missing context. The 20% is real. In the SELECT trial, 17,604 adults with existing heart disease and overweight or obesity, but no diabetes, took semaglutide 2.4 mg or placebo for about 40 months. A heart attack, stroke or cardiovascular death happened to 6.5% of the semaglutide group and 8.0% of the placebo group. That's a 20% relative drop and about 1.5 percentage points in absolute terms. Both numbers matter, and the result applies to people like those studied. Our relative vs absolute risk explainer walks through the math.

B) Spin. In June 2025 the European Medicines Agency concluded that NAION, an eye condition that can cause sudden vision loss, is a very rare side effect of semaglutide. Observational studies in adults with type 2 diabetes suggested about double the risk. In absolute terms, EMA put that at roughly one additional case per 10,000 person-years of treatment. "Doubles" is accurate. "Your risk of sudden blindness" turns a very rare event into an everyday one. The fact worth keeping: if your vision suddenly drops or gets worse fast, contact a doctor promptly.

C) Missing context, and it's out of date. On January 13, 2026, FDA asked the makers of Saxenda, Wegovy and Zepbound to remove the suicidal behavior and ideation warning from their labels. FDA's meta-analysis of 91 placebo-controlled trials with 107,910 participants found no increased risk, and a large Sentinel study of more than 2.2 million new users found no increased risk of intentional self-harm. A headline like this one may be recycling a 2023 story. FDA still says anyone with thoughts of self-harm should be referred for mental health care. In the US, call or text 988 any time.

C) Missing context. Reports to FDA's adverse event system come from patients, clinicians and companies, and FDA itself says there is "no certainty" that a suspected drug caused the event. The event could come from the illness, another medicine or chance. Reports can flag a signal worth studying, but they aren't proof. See why an adverse-event report is not proof.

B) Spin. In the 68-week trial on the Wegovy label, average weight change was −14.9% with semaglutide and −2.4% with placebo. Averages hide a spread: 47.9% of people on the medicine lost 15% or more, 66.1% lost at least 10%, and 83.5% lost at least 5%. "Users lose 15%" makes an average sound like a promise. More on this in average weight loss vs responder rates.

A) Fact, mostly. In the STEP 1 extension, people who stopped semaglutide 2.4 mg had regained about two-thirds of their lost weight a year later. They were still about 5.6% below their starting weight on average. Small print: the extension followed 327 people and was exploratory. A fair headline says "much of it, on average," not "all of it, for everyone."

B) Spin (or just wrong). Ozempic's label covers adults with type 2 diabetes: blood sugar control plus heart and kidney risk reduction in that group. The semaglutide brand approved for weight management is Wegovy. People often use "Ozempic" as slang for the whole class, but headlines shouldn't.

A) Fact, if it's dated December 2025. Novo Nordisk announced FDA approval of Wegovy tablets on December 22, 2025. Then on April 1, 2026, FDA approved Lilly's Foundayo (orforglipron). So "first" was true once and is now history. The two pills come with different instructions: Wegovy tablets are taken on an empty stomach with no more than 4 ounces of water, followed by a 30-minute wait. Foundayo can be taken with or without food. Our 2026 approvals roundup has the full list.

C) Missing context. These labels carry a boxed warning because the drugs caused thyroid C-cell tumors in rodents. The labels say it's unknown whether that happens in humans. They also say people with a personal or family history of medullary thyroid carcinoma or MEN 2 shouldn't use them. That's a real precaution, not a proven cause.

B) Spin, and a warning sign. Retatrutide is still investigational, which means it isn't FDA-approved for any use. FDA has warned companies selling retatrutide and similar products labeled "for research purposes" or "not for human consumption." The agency says the quality of those products is unknown and consumers shouldn't buy them. "Available online" here means "sold outside the system."